# A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

> **NCT06305559** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **NewAmsterdam Pharma** · enrollment: 300 (estimated)

## Conditions studied

- Lipidemia
- Coronary Artery Disease
- Plaque, Atherosclerotic

## Interventions

- **DRUG:** obicetrapib 10 mg + ezetimibe 10 mg FDC daily
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06305559
- **Lead sponsor:** NewAmsterdam Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-16
- **Primary completion:** 2027-11
- **Final completion:** 2028-02
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06305559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06305559, "A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06305559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*